Clinical characteristics and real-life diagnostic approaches in all Danish children with hereditary angioedema

Aabom, Anne; Andersen, Klaus Ejner; Fagerberg, Christina Ringmann; Fisker, Niels; Jakobsen, Marianne Antonius; Bygum, Anette

Published in:
Orphanet Journal of Rare Diseases

DOI:
10.1186/s13023-017-0604-6

Publication date:
2017

Document version
Publisher's PDF, also known as Version of record

Document license
CC BY

Citation for published version (APA):
Aabom, A., Andersen, K. E., Fagerberg, C., Fisker, N., Jakobsen, M. A., & Bygum, A. (2017). Clinical characteristics and real-life diagnostic approaches in all Danish children with hereditary angioedema. Orphanet Journal of Rare Diseases, 12, [55]. https://doi.org/10.1186/s13023-017-0604-6

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 06. feb., 2019
Clinical characteristics and real-life diagnostic approaches in all Danish children with hereditary angioedema

Anne Aabom 1,2*, Klaus E. Andersen 1,3, Christina Fagerberg 4, Niels Fisker 5, Marianne A. Jakobsen 6 and Anette Bygum 1,2

Abstract

**Background:** With a potentially early onset, hereditary angioedema (HAE) requires special knowledge also in infancy and early childhood. In children from families with HAE, the diagnosis should be confirmed or refuted early, which can be difficult. Studies of childhood HAE and the diagnostic approaches are limited. Our aim was to investigate the entire Danish cohort of children with HAE and non-HAE children of HAE patients for diagnostic approaches and clinical characteristics.

**Results:** We included 41 children: 22 with HAE and 19 non-HAE. Of the HAE children, 14 were symptomatic—median age at onset was 4 [1–11] years. The first attack was peripheral in 8/14 children and abdominal in 6/14 children, i.e. no one had their first attacks in the upper airways. Most children had less than one attack per month. All of the symptomatic children had been treated with tranexamic acid and/or C1 inhibitor concentrate. Unlike in other countries, androgens were not used in our pediatric cohort. Home therapy with C1 inhibitor concentrate was established in 9 cases: 6 children were trained in self-administration and 3 children were treated by parents. Of the children, 10 had been diagnosed by symptoms, including 3 without family history—median age of diagnosis among these children was 5.35 [2–13.2] years. In 31 children, HAE was diagnosed or refuted before symptoms by blood samples. In 23 of these children, complement values were investigated, and in 9 cases genetic testing was added to the complement measurements. In 8 children recently investigated, genetic testing was first choice. Cord blood was used for complement measurements in 9 children and for genetic testing in 4 children. Results of complement measurements were equivocal in several cases, especially in the cord blood samples, and the sensitivity of low complement C4 for the diagnosis of HAE was 75%.

**Conclusions:** We investigated clinical characteristics in all Danish children with HAE. The rate of home therapy was high and androgens had been avoided. Complement values were often equivocal, especially in cord blood samples. Consequently, we have changed diagnostic practice to early genetic testing in children where the family mutation is known.

**Keywords:** Clinical characteristics, Complement C4, Diagnosis, Genetic testing, Hereditary angioedema, Pediatric, Therapy

* Correspondence: anne.aabom@rsyd.dk
1 Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark
2 OPEN, Odense Patient data Explorative Network, Odense University Hospital, Odense, Denmark
Full list of author information is available at the end of the article

© The Author(s), 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Hereditary angioedema (HAE) is a genetic disease characterized by recurrent attacks of subcutaneous swellings and abdominal pain. It is caused by either a deficiency (HAE type I) or a reduced functional capacity (HAE type II) of complement C1 inhibitor. The age of onset is variable, but half the patients develop symptoms before the age of 10 years [1, 2]. Life-threatening attacks may occur in the upper airways, and death due to asphyxiation has been reported in children as young as 2 weeks old [3].

The course of HAE is unpredictable, and it is important to establish a diagnosis early, ideally before onset in cases with a family history. The diagnosis is based on clinical manifestations and/or family history combined with laboratory findings [4].

Diagnosis based on biochemical measurements
Biochemical investigation comprises the complement values total antigenic C1 inhibitor (C1INH), functional capacity of C1 inhibitor (fC1INH), and complement C4 (C4). According to diagnostic algorithms, a family history of angioedema should lead to complement measurement [5, 6]. For early diagnosis of newborns from HAE families, cord blood has been used [7]. There is consensus that low complement values obtained on two separate occasions (one after the age of 12 months) are required to diagnose HAE in asymptomatic children [4–6, 8]. However, most complement assays lack validated reference values for children. Furthermore, results may be equivocal despite repeated measurements and must be interpreted with caution.

Diagnosis based on genetic investigation
Alternatively to complement measurements, mutational screening of the gene encoding C1INH can be used [9]. HAE is caused by mutations in the SERPING1 gene (OMIM #606860) located on chromosome 11. The inheritance pattern is autosomal dominant, but 25% of cases are de novo mutations [10]. If the family mutation is known, children can be diagnosed early with genetic testing performed on peripheral blood or blood from the umbilical cord. Until now, this has not been recommended as first choice [11].

With a potentially early onset, HAE requires special knowledge in both diagnosis and overall management, also in infancy and early childhood. However, original studies of the special aspects of childhood HAE, including the diagnostic challenges, are limited. The aim of this study was to describe clinical features of childhood HAE and evaluate the real-life diagnostic approaches in Danish HAE families.

Methods
This retrospective study was undertaken at the Danish HAE Comprehensive Care Centre, Odense University Hospital in October 2016. Data collection began in January 2013 and children born after 1995 were included. Children were identified via a nationwide HAE registry containing data of all known Danish HAE families [12]. The search had two steps: 1) All children in the registry with a diagnosis of HAE type I or II were identified. For convenience, both symptomatic children and carriers of HAE who had not yet experienced any attacks were all labeled HAE patients. In cases with a family history of HAE, all healthy siblings were included (information about these children was retrieved from medical records of the siblings with HAE or the parents). Half-siblings were also included if they shared the parent with HAE. 2) Medical records of all adult HAE patients that were not parents of children already included were searched for information about other healthy children.

Clinical information from children with HAE (age at onset, localization of attacks, attack frequency, and use of therapy) was retrieved from the medical records. The observation period for attack frequency and use of therapy was 45 months (January 2013–October 2016). During this observation period, children were excluded when they turned 18 years old. Information on the diagnostic process was retrieved from the medical records.

Results of complement measurements and genetic testing were recorded in a research database. C1INH and C4 were measured with nephelometry, turbidimetry, or rocket immunoelectrophoresis and fC1INH with chromogenic assays. Mostly, the analyses were performed by Unilabs, Copenhagen, but in some cases they were performed by other laboratories in Denmark or abroad. In each case, the complement results were interpreted against the performing laboratories’ reference range for healthy adults. On this background, complement values were categorized as "normal" (values within or above adult normal range), “low” (values below adult normal range), or “equivocal” (cases with inconsistency, e.g. low C1INH combined with normal C4). Genetic testing for mutations in the SERPING1 gene were performed with Sanger sequencing or Multiplex Ligation-dependent Probe Amplification (MLPA) analysis. Parental written consent to investigate the medical records and to contact previous healthcare professionals was granted, and the study was approved by the Danish Data Protection Agency (14/38996).

Results
In 18 of 35 Danish HAE families, we identified 41 children (27 boys, 14 girls) eligible for the study; all agreed to participate. Of these children, 22 had HAE (3 had type II) and 19 had not (named non-HAE). Among the 19 non-HAE children, all had a parent with HAE and 10 also had a sibling with HAE. Among the 22 children with HAE, 14 were symptomatic. Clinical characteristics are outlined in Table 1.
Home therapy with C1INH concentrate was established in 9 cases. In 6 cases, the child was trained in self-administration (at the age 10.4–16.4 years), and in 3 cases treatment was administered by parents (established when children were 5.8–12.1 years old).

The results of all diagnostic blood samples for children in the cohort are outlined in Tables 3 and 4. Mostly, C1INH and C4 had been measured with nephelometry or turbidimetry, and fC1INH with chromogenic assays. In one case, C1INH had been measured with rocket immunoelectrophoresis (HAE5). In a few medical records, “normal” complement values were reported, but the exact laboratory data could not be retrieved. These missing values were noted in the study, but were not given any diagnostic weight.

The diagnostic approaches are summed in Fig. 1. Of the children, 7 had symptoms before they were tested. Of these 7 children, 3 had no family history; one had a proven de novo mutation, and the parents of the other 2 were asymptomatic with normal C1INH values. Median diagnostic delay in the children with sporadic HAE was 2.8 [2.2–4.8] years versus 1.0 [0.5–1.3] years in cases with a family history. Another 3 children from HAE families were diagnosed at symptom onset based on older blood samples, e.g. their diagnosis was formally established when they had their first attack. Median age of diagnosis among all 7 children diagnosed by symptoms with a family history was 4.4 [2–6.3] years, and for the 3 without family history 8.8 [6.8–13.2] years.

In 31 children, HAE was diagnosed or refuted prior to any symptoms by laboratory testing at mean age 0.4 [0–18.1] years. In 23 of these children, complement values were investigated. In most cases, two complement measurements were performed with at least one occurring after the age of 1 year, but in 7 children HAE was refuted by only one normal complement measurement. Genetic testing was added in 9 other children whose diagnostic course was characterized by repeated complement measurements with incomplete or equivocal results. In 8 children recently investigated, genetic testing was the first choice (at age 0–18.1 years). The mean age of diagnosis or refutation of HAE for all 38 children born into HAE families was 1.5 [0–18.1] years.

Cord blood was used for complement measurements in 9 children and for genetic testing in 4 children. Cord blood complement values were low in 5 children with HAE and equivocal in 4 children (2 with HAE and 2 non-HAE). Results were equivocal in 44% of the complement measurements performed on cord blood compared with 20% (12/60) of the peripheral complement measurements in the cohort.

### Discussion

We investigated clinical features and real-life diagnostic approaches in 41 children from Danish HAE families.
| ID  | sex | Born | Age at onset/ diagnosis | Cord blood samples [reference values for adults] | Peripheral complement measurements [reference values for adults] | Genetic testing b |
|-----|-----|------|-------------------------|-----------------------------------------------|------------------------------------------------------------|----------------|
| HAE1 | f   | 1995 | 5/6 y                  | n.d.                                         | 6 y C1INH 34 [70–130]%                                   | 11.6 y C1INH 129 [210–345]mg/L |
|     |     |      |                        |                                              | C1INH 0.15 [0.21–0.39]g/L                                | C1INH 9.2 [172–274]U/ml       |
|     |     |      |                        |                                              | C1INH 55 [70–130]%                                      | C4 0.13 [0.1–0.4]g/L          |
|     |     |      |                        | Complement values reported as normal (missing) | 8.8 y                                      | 2.8 y C1INH 49 [70–130]%                                    |
|     |     |      |                        |                                              | C1INH 0.12 [0.21–0.39]g/L                                | C1INH 0.13 [0.21–0.39]g/L     |
|     |     |      |                        |                                              | C1INH 32% [70–130]                                      | C4 0.15 [0.1–0.4]g/L          |
|     |     |      |                        |                                              | C4 0.08 [0.1–0.4]g/L                                    | C4 0.08 [0.1–0.4]g/L          |
|     |     |      |                        |                                              | n.d.                                                      | n.d.                         |
| HAE2 | f   | 1995 | 5/6.3 y                | Complement values reported as normal (missing) | 9.5 y                                      | 13.7 and 15.1 y c.1030_1503del, deletion of exons 7 and 8 |
|     |     |      |                        |                                              | C1INH 0.05 [0.21–0.39]g/L                                | C1INH <25 | 13.2 y C1INH <25 [72–153]% |
|     |     |      |                        |                                              | C1INH 33 [70–130]%                                      | C1INH 27 [70–130]%            |
|     |     |      |                        |                                              | C4 0.08 [0.1–0.4]g/L                                    | C4 < 0.04 [0.1–0.4]g/L        |
|     |     |      |                        |                                              | n.d.                                                      | n.d.                         |
| HAE3 | m   | 1996 | 4/4 y                  | n.d.                                         | 6.8 y                                      | 7.3 y C1INH 0.13 [0.21–0.39]g/L                             |
|     |     |      |                        |                                              | C1INH 0.05 [0.21–0.39]g/L                                | C1INH 0.14 [0.21–0.39]g/L     |
|     |     |      |                        |                                              | C1INH 122 [70–130]%                                     | C1INH 2 [70–130]%             |
|     |     |      |                        |                                              | C4 0.07 [0.1–0.4]g/L                                    | C4 < 0.04 [0.1–0.4]g/L        |
|     |     |      |                        |                                              | n.d.                                                      | n.d.                         |
| HAE4 | f   | 1996 | 1/2 y                  | n.d.                                         | 8.5 y                                      | 7.5 y c.1381G > C, p.Ala439Pro                                |
|     |     |      |                        |                                              | C1INH 0.06 [0.21–0.39]g/L                                | C4 0.15 g/L                   |
|     |     |      |                        |                                              | C1INH 39 [70–130]%                                      | [0.1–0.4]g/L                   |
|     |     |      |                        |                                              | C4 0.07 [0.1–0.4]g/L                                    | [0.1–0.4]g/L                   |
|     |     |      |                        |                                              | n.d.                                                      | n.d.                         |
| HAE5 | f   | 1999 | 11/13.2 y              | n.d.                                         | 13.5 y                                      | 13.7 and 15.1 y c.23dupT, X19 in signal peptide             |
|     |     |      |                        |                                              | C1INH 0.08 [0.21–0.39]g/L                                | C1INH 0.14 [0.21–0.39]g/L     |
|     |     |      |                        |                                              | C1INH 46 [70–130]%                                      | C1INH 2 [70–130]%             |
|     |     |      |                        |                                              | C4 < 0.06 [0.1–0.4]g/L                                  | C4 < 0.06 [0.1–0.4]g/L        |
|     |     |      |                        |                                              | n.d.                                                      | n.d.                         |
| HAE6 | m   | 2000 | 3/3 y                  | n.d.                                         | 13.2 y                                      | 9.8 y c.1030_1503del, deletion of exons 7 and 8             |
|     |     |      |                        |                                              | C1INH 0.09 [0.21–0.39]g/L                                | C1INH 0.07 [0.21–0.39]g/L     |
|     |     |      |                        |                                              | C1INH 0.09 [70–130]%                                     | C1INH 32% [70–130]            |
|     |     |      |                        |                                              | C4 0.05 [0.16–0.38]g/L                                   | C4 0.07 [0.1–0.4]g/L          |
|     |     |      |                        |                                              | n.d.                                                      | n.d.                         |
| HAE7 | m   | 2000 | 4/8.8 y                | n.d.                                         | 8.8 y                                      | 9.8 y c.1030_1503del, deletion of exons 7 and 8             |
|     |     |      |                        |                                              | C1INH 0.07 [0.21–0.39]g/L                                | C1INH 0.14 [0.21–0.39]g/L     |
|     |     |      |                        |                                              | C1INH 32 [70–130]%                                      | C1INH 2 [70–130]%             |
|     |     |      |                        |                                              | C4 0.07 [0.1–0.4]g/L                                    | C4 < 0.04 [0.1–0.4]g/L        |
|     |     |      |                        |                                              | n.d.                                                      | n.d.                         |
| HAE8 | f   | 2000 | 4/6.8 y                | n.d.                                         | 6.9 y                                      | 7.5 y c.1381G > C, p.Ala439Pro                                |
|     |     |      |                        |                                              | C1INH 0.14 [0.21–0.39]g/L                                | C1INH 129 [210–345]mg/L       |
|     |     |      |                        |                                              | C1INH 2 [70–130]%                                       | C1INH 9.2 [172–274]U/ml       |
|     |     |      |                        |                                              | C4 < 0.04 [0.1–0.4]g/L                                  | C4 0.13 [0.21–0.39]g/L        |
|     |     |      |                        |                                              | n.d.                                                      | C4 0.08 [0.1–0.4]g/L          |
|     |     |      |                        |                                              | n.d.                                                      | n.d.                         |
| HAE9 | f   | 2001 | 10/1.6 y               | C1INH 0.07 g/L [0.21–0.39]                   | 1.6 y                                       | 7.5 y C1INH 0.13 [0.21–0.39]g/L                             |
|     |     |      |                        | C1INH 32% [70–130]                          | C1INH 0.12 [0.21–0.39]g/L                          | C1INH 0.14 [0.21–0.39]g/L     |
|     |     |      |                        | C4 0.15 g/L [0.1–0.4]                        | C4 0.08 [0.1–0.4]g/L                                    | C4 0.15 [0.1–0.4]g/L          |
| HAE10  | 2004  | 4.2/4.7 y | n.d. | 4.7 y | C1INH 0.06 | 0.21–0.39 g/L | fC1INH 32 | (70–130)% | 4.8 y | C1INH 61 | 0.21–0.39 g/L | fC1INH <2 | (172–274)U/ml | C4 68 | 157–257 mg/L |
|--------|-------|-----------|------|-------|------------|---------------|-----------|----------|-------|------------|---------------|-----------|----------------|------|-------------|
| HAE11  | 2004  | -/5.7 y   | n.d. | 5 y   | C1INH 0.44 | 0.21–0.39 g/L | fC1INH 32 | (70–130)% | 61     | C1INH 0.34 | 0.21–0.39 g/L | fC1INH <2 | (70–130)% |
|        | m     | type II   |      |       | C1INH 0.06 | 0.21–0.39 g/L | fC1INH <2 | (70–130)% | C4 0.07 | (0.1–0.4) g/L |
|        | m     |          |      |       |            |               |           |          |        |             |               |           |               |      |             |
| HAE12  | 2006  | 4/4.4 y   |      |       | C1INH 0.05 | 0.21–0.39 g/L | fC1INH 37 | (70–130)% | 0.44   | (0.21–0.39) g/L | fC1INH <2 | (70–130)% | C4 0.1 | (0.1–0.4) g/L |
|        | m     |          |      |       |            |               |           |          |        |             |               |           |               |      |             |
| HAE13  | 2006  | 5.4/3.8 y |      |       | C1INH  69 | 0.1–0.4) g/L | fC1INH 69 | (70–130)% | 0.07   | (0.1–0.4) g/L | fC1INH <2 | (70–130)% | C4 0.1 | (0.1–0.4) g/L |
|        | m     |          |      |       |            |               |           |          |        |             |               |           |               |      |             |
| HAE14  | 2008  | 3.3/2.7 y |      |       | C1INH  <0.03 | 0.21–0.39 g/L | fC1INH 65 | (70–130)% | 0.04   | (0.1–0.4) g/L | fC1INH <2 | (70–130)% | C4 0.04 | (0.1–0.4) g/L |
|        | m     |          |      |       |            |               |           |          |        |             |               |           |               |      |             |
| HAE15  | 2009  | -/5.3 y   | n.d. | 2.4 y | C1INH 0.16 | 0.21–0.39 g/L | fC1INH 65 | (70–130)% | 0.11   | (0.1–0.4) g/L | fC1INH <2 | (70–130)% | C4 0.1 | (0.1–0.4) g/L |
|        | m     |          |      |       |            |               |           |          |        |             |               |           |               |      |             |
| HAE16  | 2009  | 3.8/1 y   |      |       | C1INH  <0.03 | 0.21–0.39 g/L | fC1INH 52 | (70–130)% | 0.13   | (0.1–0.4) g/L | fC1INH <2 | (70–130)% | C4 0.1 | (0.1–0.4) g/L |
|        | m     |          |      |       |            |               |           |          |        |             |               |           |               |      |             |
| HAE17  | 2012  | -/2.8 y   | n.d. | 1 y   | C1INH 0.13 | 0.21–0.39 g/L | fC1INH 52 | (70–130)% | 0.11   | (0.1–0.4) g/L | fC1INH <2 | (70–130)% | C4 0.1 | (0.1–0.4) g/L |
|        | m     | type II   |      |       |            |               |           |          |        |             |               |           |               |      |             |
| HAE18  | 2012  | -/2.1 y   | n.d. |       |           |               |           |          |        |             |               |           |               |      |             |
| HAE19  | 2012  | -/1.8 y   |      |       | K1INH 20 | 0.21–0.39 g/L | fC1INH 56 | (70–130)% | 0.10   | (0.1–0.4) g/L | fC1INH <2 | (70–130)% | C4 0.1 | (0.1–0.4) g/L |
|        | m     |          |      |       |            |               |           |          |        |             |               |           |               |      |             |
| HAE20  | 2013  | -/0.5 y   |      |       | C1INH 0.08 | 0.21–0.39 g/L | fC1INH 56 | (70–130)% | 0.14   | (0.1–0.4) g/L | fC1INH <2 | (70–130)% | C4 0.1 | (0.1–0.4) g/L |

**Table 3** Results of diagnostic blood samples in 22 children with HAE (Continued)
Median age at onset was 4 [1–11] years, which is in accordance with a recent Swedish pediatric HAE study [13]. In the other few original studies dedicated to pediatric HAE, age at onset was slightly higher: in a Hungarian study median age at onset was 5 years [14], and in two US studies it was 5.7 and 7 years, respectively [15, 16]. Like Farkas et al., we found that the first attack was most commonly peripheral, closely followed by abdominal attacks (Table 1) [17]. No one had their first attacks in the upper airways. All symptomatic children had experienced abdominal attacks, whereas peripheral and upper airway attacks had occurred in 79% and 29% of the children, respectively. Numbers are similar to those previously reported [16]. Most children had less than one attack per month, which differs from a Hungarian study with 11 of 26 children having frequent attacks [18]. In contrast to a large US study, we found no correlation between age at onset and disease severity (our surrogate measure for disease severity was number of attacks) [19].

Most of the treated children had tried more than one type of therapy, which emphasizes the need for a tailored approach. Unlike other countries [16, 20, 21], androgens were not used in our pediatric cohort. This is noteworthy, because the use of androgens in children with HAE and the potential adverse effects are continuously debated [6, 22]. Home therapy with intravenous CIINH concentrate was established in 9 (64%) of the symptomatic children. Conversely, only 2 of 111 children (1.8%) administered intravenous therapy at home in a UK study, and 28% of treated children were managed at home in Hungary [14, 21]. In our cohort, the youngest child having treatment administered by parents was 5 years old, and the youngest child trained in self-administration was 10 years old. The rate of children able to self-administer was 6 of 9 (67%), which is considerably higher than previously reported [23].

In our cohort, 24% of the children were diagnosed by symptoms and the diagnosis was confirmed by blood testing. This is comparable to 21% in a previous study that also includes children with sporadic HAE [17]. The median diagnostic delay among children with sporadic HAE in our study was 2.8 years compared with a diagnostic delay of 6 years in children without family history in a US study [16].

The mean age at which HAE was diagnosed or refuted was 1.5 years among the 38 children born into HAE families. This is considerably lower than studies including adult patients [1, 19] and also other pediatric studies [13, 15–17]. However, HAE was refuted by only one set of normal complement values in 7 non-HAE children, which must be considered insufficient. Thus, the most recent consensus paper on pediatric HAE specifies that asymptomatic children with a family history of HAE should be considered to have HAE until the diagnosis is ruled out by two complement measurements with at least one of them performed after the age of 1 year [6]. Among children with a family history of HAE, 7 developed symptoms before the diagnosis was formally established with two complement measurements. This is not optimal, as milder HAE symptoms might be missed if children do not have a certified diagnosis.

However, complement measurements do not always give clear results. Complement values can show considerable age-specific variations in children [7, 24–27], and most complement assays do not have reference levels for children. In our cohort, equivocal or incomplete complement results occurred in several cases. This differs from a Spanish HAE study demonstrating a very good agreement between complement values and genetic testing in children [28]. However, only 9 children under the age of 1 year were included. In that study, only C4 was found unreliable, because values were falsely low in 5 non-HAE children. We found, however, 7 cases of C4 values within adult normal range among children with HAE (all without symptoms and untreated when blood samples were taken). As C4 was measured 28 times among children with HAE in our cohort, the sensitivity of low C4 for the diagnosis of HAE was 75% (21/28), which is comparable to a 81% sensitivity previously found [29].

The use of cord blood samples in our cohort seems worth exploring. Among the 9 cord blood complement measurements performed, 4 had equivocal results. In addition, there seemed to be practical challenges of handling blood for the sensitive complement assays in a delivery room as another 3 cord blood samples were
| ID | sex | Born | Age when HAE was refuted | Cord blood samples [reference values for adults] | Peripheral complement measurements [reference values for adults] | Genetic testing |
|----|-----|------|--------------------------|-----------------------------------------------|----------------------------------------------------------|-----------------|
| Non1 | m | 1996 | 4.8 y | n.d. | 4.8 y C1INH 121 [70–130] % | n.d. |
| Non2 | m | 1997 | 1.5 y | n.d. | 1.5 y C1INH 162 [80–140] units C1INH 168 [70–130] % | n.d. |
| Non3 | m | 1997 | 18.1 y | n.d. | 2.9 y Reported as normal, but missing | 18.1 y Family mutation ruled out |
| Non4 | f | 1997 | 14.9 y | n.d. | <14.6 y (exact age unknown) Reported as normal (missing) | 14.9 y C1INH 0.33 [0.21–0.39] g/L C1INH 120 [70–130] % C4 0.18 [0.1–0.4] g/L | n.d. |
| Non5 | m | 1999 | 15.7 y | n.d. | 0.1 y C1INH 81 [70–130] % | 15.7 y Family mutation ruled out |
| Non6 | m | 1999 | 16.1 y | n.d. | 1.0 y C1INH 166 [70–130] % | 16.1 y Family mutation ruled out |
| Non7 | f | 1999 | 1.9 y | n.d. | 1.9 y C1INH 110 [70–130] % | n.d. |
| Non8 | f | 2000 | 6.4 y | n.d. | 6.4 y C1INH 0.27 [0.21–0.39] g/L C1INH 106 [70–130] % C4 0.2 [0.1–0.4] g/L | n.d. |
| Non9 | m | 2000 | 5.9 y | n.d. | 4.3 y C1INH 0.34 [0.21–0.39] g/L C1INH 129 [70–130] % C4 0.11 [0.1–0.4] g/L | n.d. |
| Non10 | m | 2002 | 9.1 y | n.d. | 9.1 y C1INH 0.38 [0.21–0.39] g/L C1INH 116 [70–130] % C4 0.27 [0.1–0.4] g/L | n.d. |
| Non11 | m | 2003 | 3.2 y | n.d. | 1.5 y C1INH 0.38 [0.21–0.39] g/L C1INH 117 [70–130] % C4 0.13 [0.1–0.4] g/L | n.d. |
| Non12 | m | 2008 | 1.3 y | n.d. | 1.3 y C1INH 0.33 [0.21–0.39] g/L C1INH 174 [70–130] % C4 0.33 [0.1–0.4] g/L | n.d. |
| Non13 | m | 2008 | 1 y | Taken, but not analyzed | 0.8 y C1INH 0.41 [0.21–0.39] g/L C1INH 179 [70–130] % C4 0.31 [0.1–0.4] g/L | n.d. |
| Non14 | m | 2009 | 4.4 y | n.d. | 2.4 y C1INH 0.3 [0.21–0.39] g/L C1INH 130 [70–130] % C4 0.26 [0.1–0.4] g/L | 5.3 y Family mutation ruled out |
| Non15 | f | 2009 | 1 y | C1INH 0.2 [0.21–0.39] g/L C4 0.14 [0.1–0.4] g/L | 1 y C1INH 0.43 [0.21–0.39] g/L C1INH 168 [70–130] % C4 0.21 [0.1–0.4] g/L | 1 y Family mutation ruled out |
| Non16 | m | 2010 | 0.3 y | C1INH 0.17 [0.21–0.39] g/L C4 0.16 [0.1–0.4] g/L | 1.4 y C1INH 0.57 [0.21–0.39] g/L C1INH 252 [70–130] % C4 0.5 [0.1–0.4] g/L | 0.3 y Family mutation ruled out |
| Non17 | m | 2013 | 0 y | Taken for complement measurement, but mishandled. Instead used for genetic testing. | | |
mishandled so useful results could not be obtained. To our knowledge, these data form the largest material published on cord blood samples in children from HAE families. A previous study reported data from cord blood in 2 children of HAE patients, of whom one developed HAE [7]. The fluctuating nature of complement values in cord blood has been of concern in international papers [11, 30]. Our findings support that concern and the method is not used anymore at the Danish HAE Centre. Overall, our results sustain the recommendation that complement measurements performed before the age of 1 year should be interpreted with caution [6].

In our experience, some families find it difficult to wait for their child’s HAE diagnosis to be confirmed or refuted by repeated complement measurements. Likewise, physicians are challenged on establishing emergency plans with pediatricians and emergency rooms while the diagnosis is pending. Genetic testing can be helpful in equivocal cases, but until now it has not been recommended as first choice [11]. Moreover, mutations cannot be identified in around five percent of the cases even in clear-cut HAE families [9, 31]. In our cohort, several infants were investigated early by genetic testing, which may partly explain why age at diagnosis was lower in this study. Genetic testing also provided a final answer in some challenging cases and as a consequence it has been our first choice in the most recent cases. It is less sensitive to sample handling compared with complement measurements, and with a known family mutation the genetic analysis has 100% sensitivity and specificity. Also the expense of genetic testing is decreasing. Complement assays are less expensive, but it takes at least two measurements to confirm the diagnosis. Furthermore, there are costs related to having a child under observation for HAE, e.g. supply of emergency medicine. Also the psychological burden of an unresolved case is an important issue.

### Table 4 Results of diagnostic blood samples in 19 non-HAE children (Continued)

| Non18 | 2014 | 0 y | n.d. | Non19 | 2015 | 0 y | Genetic testing, family mutation |
|-------|------|-----|------|-------|------|-----|---------------------------------|
| f     |      |     |      | f     |      |     | ruled out                       |

Complement values were equivocal (bold font) or normal compared with adult normal range

N.d. not determined

---

Fig. 1 The diagnostic approaches in 41 children investigated for hereditary angioedema
Conclusions
We have investigated clinical characteristics of all Danish children with HAE. The age at onset was slightly lower than in other studies, but the distribution of the first attacks was similar to other cohorts. Like in other studies, abdominal and peripheral attacks were the most common and upper airway attacks relatively rare. The rate of home therapy was high and androgens had been avoided.

As the first, we have thoroughly investigated the diagnostic approaches in all children from an entire national HAE cohort, and we present the largest material published on cord blood samples in children from HAE families. Complement values were often equivocal, especially in cord blood samples, and the sensitivity of low C4 for the diagnosis of HAE was only 75%. Consequently, we have changed diagnostic practice and do not use cord blood for complement measurements anymore. Instead, we will advocate for early postnatal genetic testing in children where the family mutation is known.

Abbreviations
C1INH: C1 inhibitor; C4: Complement factor C4; FC1INH: Functional C1 inhibitor; HAE: Hereditary angioedema; MLPA: Multiplex Ligation-dependent Probe Amplification

Acknowledgements
Not applicable.

Funding
“This work was supported by the Lundbeck Foundation”.

Availability of data and materials
The datasets generated and analyzed during the current study are not publicly available because they are derived from medical records but are available from the corresponding author on reasonable request.

Authors’ contributions
AA and AB collected data from the medical records and wrote the manuscript draft. KEA and NF contributed to data interpretation and adjustments of the manuscript. CF and MJ analyzed and interpreted the blood samples for genetic testing. All authors read and approved the final manuscript.

Authors’ information
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Parental written consent to investigate the medical records and to contact previous healthcare professionals was granted. The study was reported to The Regional Committees on Health Research Ethics for Southern Denmark but the need for approval was waived.

Author details
1Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark. 2OPEN, Odense Patient data Explorative Network, Odense University Hospital, Odense, Denmark. 3Center for Innovative Medical Technology, Institute for Clinical Research, University of Southern Denmark, Odense, Denmark. 4Department of Clinical Genetics, Odense University Hospital, Odense, Denmark. 5Hans Christian Andersen Children’s Hospital, Odense University Hospital, Odense, Denmark. 6Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.

Received: 29 November 2016 Accepted: 27 February 2017
Published online: 16 March 2017

References
1. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119:267–74.
2. Björkander J, Bygum A, Nielsen EW. Hereditary angioedema—difficult disease with new therapeutic options. Lakartidningen. 2012;109:99–103.
3. Morris R. Final note on Case II of Angioneurotic Oedema. Am J Med Sci. 1905;130:382–6.
4. Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet. 2012;379:474–81.
5. Craig T, Avery-Casson C, Bork K, Bowen T, Boysen H, Farkas H, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J. 2012;5:182–99.
6. Farkas H, Martinez-Saguer I, Bork K, Bowen T, Craig T, Frank M, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017;72:300–13.
7. Nielsen EW, Johansen HT, Holt J, Molines TE. C1 inhibitor and diagnosis of hereditary angioedema in newborns. Pediatr Res. 1994;35:184–7.
8. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, et al. International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6:24. Off. J. Can. Soc. Allergy Clin. Immunol.
9. Bygum A, Fagerberg CR, Ponard D, Monnier N, Lunardi J, Droett C. Mutational spectrum and phenotypes in Danish families with hereditary angioedema because of C1 inhibitor deficiency. Allergy. 2011;66:76–84.
10. Pappalardo E, Cicardi M, Duponchel C, Carugati A, Choquet S, Agostoni A, et al. Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema. J Allergy Clin Immunol. 2000;106:147–54.
11. Farkas H, Varga L, Széplaki G, Wisi B, Hammat G, Bowen T. Management of hereditary angioedema in pediatric patients. Pediatrics. 2007;120:e713–22.
12. Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol. 2009;161:1153–8.
13. Rydberg A, Nordenfelt P, Lindfors A, Mallbris L, Björkander J, Wahling-CF. Swedish children with hereditary angioedema report good overall health and quality of life despite symptoms. Acta Paediatr. 2016;105:529–34.
14. Farkas H, Csuka D, Zetter Z, Szabó E, Czalier I, Varga L, et al. Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients. J Allergy Clin Immunol. 2013;131:909–11.
15. Bennett G, Craig T. Hereditary angioedema with a focus on the child. Allergy Asthma Proc. 2015;36:70–3. Off J. Reg. State Allergy Soc.
16. Nanda MK, Elenburg S, Bernstein JA, Assa-Aajdi A. Clinical features of pediatric hereditary angioedema. J Allergy Clin Immunol Pract. 2015;3:392–5.
17. Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol. 2010;6:18. Off. J. Can. Soc. Allergy Clin. Immunol.
18. Farkas H, Hammat G, Füst G, Varga L, Wisi B. Clinical management of hereditary angio-oedema in children. Pediatr Allergy Immunol. 2002;13:153–61. Off. Publ. Eur. Soc. Pediatr Allergy Immunol.
19. Christiansen SC, Davis DK, Castaldo AJ, Zuraw BL. Pediatric hereditary angioedema: onset, diagnostic delay, and disease severity. Clin Pediatr (Phila). 2016;55:935–42.
20. Farkas H, Csuka D, Zetter Z, Varga L, Füst G. Prophylactic therapy in children with hereditary angioedema. J Allergy Clin Immunol. 2013;131:579–82.e1-2.
21. Read N, Lim E, Tarzi MD, Hildick-Smith P, Burns S, Fidler KJ. Paediatric hereditary angioedema: a survey of UK service provision and patient experience. Clin Exp Immunol. 2014;178:483–8.
22. Craig TJ, Schneider LC, MacGinnitie AJ. Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients: A systematic review. Pediatr Allergy Immunol. 2015;26:537–44. Off. Publ. Eur. Soc. Pediatr Allergy Immunol.
23. Keuz W, Rusicke E, Martinez-Saguer I, Avery-Casson C, Helliger C, Klingebiel T. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion (Paris). 2012;52:100–7.
24. Agostoni A, Ayyagore-Pursin E, Blinkley KE, Blanch A, Bork K, Bouillet L, et al. Hereditary and acquired angioedema: problems and progress: proceedings

Abbreviations
C1INH: C1 inhibitor; C4: Complement factor C4; FC1INH: Functional C1 inhibitor; HAE: Hereditary angioedema; MLPA: Multiplex Ligation-dependent Probe Amplification

Acknowledgements
Not applicable.

Funding
“This work was supported by the Lundbeck Foundation”.

Availability of data and materials
The datasets generated and analyzed during the current study are not publicly available because they are derived from medical records but are available from the corresponding author on reasonable request.

Authors’ contributions
AA and AB collected data from the medical records and wrote the manuscript draft. KEA and NF contributed to data interpretation and adjustments of the manuscript. CF and MJ analyzed and interpreted the blood samples for genetic testing. All authors read and approved the final manuscript.

Authors’ information
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Parental written consent to investigate the medical records and to contact previous healthcare professionals was granted. The study was reported to The Regional Committees on Health Research Ethics for Southern Denmark but the need for approval was waived.

Author details
1Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark. 2OPEN, Odense Patient data Explorative Network, Odense University Hospital, Odense, Denmark. 3Center for Innovative Medical Technology, Institute for Clinical Research, University of Southern Denmark, Odense, Denmark. 4Department of Clinical Genetics, Odense University Hospital, Odense, Denmark. 5Hans Christian Andersen Children’s Hospital, Odense University Hospital, Odense, Denmark. 6Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.

Received: 29 November 2016 Accepted: 27 February 2017
Published online: 16 March 2017
of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114:551–131.
25. Grumach AS, Cecconi ME, Rutz R, Fertig A, Kirschfink M. Complement profile in neonates of different gestational ages. Scand J Immunol. 2014;79:276–81.
26. Lockitch G, Halstead AC, Quigley G, MacCallum C. Age- and sex-specific pediatric reference intervals: study design and methods illustrated by measurement of serum proteins with the Behring LN Nephelometer. Clin Chem. 1988;34:1618–21.
27. Davis CA, Vallota EH, Forristal J. Serum complement levels in infancy: age related changes. Pediatr Res. 1979;13:1043–6.
28. Pedrosa M, Phillips-Angles E, Lope-Lera A, Lope-Trascasa M, Caballero T. Complement study versus CINH-gene testing for the diagnosis of type I hereditary angioedema in children. J Clin Immunol. 2016;36:16–8.
29. Tarzi MD, Hickey A, Förster T, Mohammadi M, Longhurst HJ. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angioedema. Clin Exp Immunol. 2007;149:513–6.
30. Caballero T, Farkas H, Bouillet L, Bowen T, Gompel A, Fagerberg C, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129:308–20.
31. Pappalardo E, Caccia S, Suffritti C, Tordai A, Zingale LC, Cicardi M. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. Mol Immunol. 2008;45:3536–44.